Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 2b Trial of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee
2019-004515-31Phase 2Completed
- Sponsor
- Nordic Bioscience
- Start
- Dec 2019
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of SB-061 in knee osteoarthritis (OA), sponsored by Nordic Bioscience. Primary endpoint: Change from baseline in knee pain at week 8. Started Dec 2019; status: completed.
02
Drugs
SB-061
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2019-004515-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004515-31.